Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Total Debt: 2019-2025

Historic Total Debt for Puma Biotechnology (PBYI) over the last 6 years, with Sep 2025 value amounting to $33.7 million.

  • Puma Biotechnology's Total Debt fell 56.82% to $33.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.7 million, marking a year-over-year decrease of 56.82%. This contributed to the annual value of $67.0 million for FY2024, which is 32.72% down from last year.
  • According to the latest figures from Q3 2025, Puma Biotechnology's Total Debt is $33.7 million, which was down 24.85% from $44.9 million recorded in Q2 2025.
  • Puma Biotechnology's 5-year Total Debt high stood at $100.1 million for Q2 2021, and its period low was $33.7 million during Q3 2025.
  • Moreover, its 3-year median value for Total Debt was $89.1 million (2024), whereas its average is $78.7 million.
  • In the last 5 years, Puma Biotechnology's Total Debt soared by 600.93% in 2021 and then slumped by 56.82% in 2025.
  • Over the past 5 years, Puma Biotechnology's Total Debt (Quarterly) stood at $97.1 million in 2021, then increased by 1.25% to $98.3 million in 2022, then grew by 1.37% to $99.7 million in 2023, then tumbled by 32.72% to $67.0 million in 2024, then plummeted by 56.82% to $33.7 million in 2025.
  • Its last three reported values are $33.7 million in Q3 2025, $44.9 million for Q2 2025, and $56.0 million during Q1 2025.